Organisation paid for research Program year 2025 Source: CMS Open Payments

Luxurgery LLC

Neither a doctor nor a teaching hospital

Research payments

$985,222

91 payments

Through program year 2025, Luxurgery LLC is reported as receiving $985,222 in research payments, across 91 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$295,136	23
2024	Research	$187,708	8
2023	Research	$158,940	27
2022	Research	$343,437	33

Breakdown

Who paid Research payments · program years 2022–2025

AbbVie, Inc. $729,250 54 payments
Endo Pharmaceuticals Inc. $255,972 37 payments

Studies the money was for Research payments · program years 2022–2025

BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study $277,690 13 payments
A Phase 2B, Open-Label Long-Term Durability Study of CCH Following Treatment of Edematous Fibrosclerotic Panniculopathy (Cellulite) $255,972 37 payments
A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence $225,436 20 payments
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) $80,538 9 payments
M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study $74,027 3 payments
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study $26,429 1 payment
A 26-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder $12,970 2 payments
M24-704 - A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) $9,329 1 payment
BOTOX? (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study $8,000 1 payment
A 26-Week Multicenter Open-Label Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia Bipolar I Disorder or Autism Spectrum Disorder $7,410 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.